Developer docs
API playgroundTry for free, no card

Search company profiles

Karius

Full company profile

uuid0000cgk

Namestring
Karius
Legal namestring
Karius, Inc.
Websiteurl
kariusdx.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Karius, Inc. is a Redwood City, California-based clinical metagenomics company founded in 2014 on intellectual property developed at Stanford University. It operates a CLIA-certified, CAP-accredited, ISO 15189-accredited clinical laboratory that processes microbial cell-free DNA (mcfDNA) sequencing tests on behalf of licensed healthcare providers. Its commercial product portfolio centers on two laboratory-developed tests: Karius Spectrum, a plasma-based test that detects over 1,000 fungi, bacteria, parasites, and DNA viruses from a single blood draw with results typically available within one day, and Karius Focus | BAL, a bronchoalveolar lavage fluid-based test launched in April 2025 that detects over 500 lung-infection pathogens from 1 mL of BAL fluid. Both are powered by the Karius Helion platform, which combines a "Direct-to-Library" chemistry that bypasses DNA extraction, a proprietary curated reference database of 20,000+ microbial sequences, and machine learning models that are continuously refined as additional patient data is processed.

Karius sells these tests as laboratory-developed tests through an enterprise field sales motion to 600+ leading US hospitals and transplant centers, with results delivered through an online portal and specimens transported via covered UPS Next Day Air Early shipping. Revenue is generated per test through institutional and payer billing, with secondary commercial activity in biopharma services (microbial liquid biopsy for clinical trial enrichment, safety monitoring, and patient stratification). The company complements its direct sales channel with Medical Science Liaisons, diagnostic stewardship support, an Investigator-Initiated Studies Grants program, and — announced in April 2026 — a collaboration with Mayo Clinic Laboratories that makes its tests available through Mayo's ordering infrastructure.

The company has raised approximately $354M in cumulative equity and debt funding across multiple rounds, including a $100M round in May 2024 co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, and received FDA Breakthrough Device Designation for its infectious disease test in May 2024. Karius reports that more than 100,000 patient samples have been tested on its platform and that the technology is supported by 300+ peer-reviewed publications. Leadership includes CEO Alec Ford, CSO Tim Blauwkamp PhD, CTO/Business Officer Sivan Bercovici PhD, CMO Bradley Perkins MD, CFO Bill Quirk, CCO Mark Aguillard, and CPO Stacy Aurora, with co-founders Tim Blauwkamp and Mickey Kertesz and Stanford's Steve Quake serving on the scientific advisory board.

Short descriptiontext

Karius is a clinical metagenomics company that delivers rapid infectious disease diagnostics to hospitals and transplant centers, detecting over 1,000 pathogens from a single blood draw via its proprietary Helion sequencing platform, AI-driven reference database, and CLIA-certified laboratory.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metagenomic sequencing diagnostics, infectious disease testing, microbial cell-free DNA, clinical laboratory diagnostics, pathogen detection services
Industry1 code
PRIMARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Infectious Disease Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Laboratory Testing Services
TypeSubscription Recurring
Description

Karius operates as a clinical laboratory offering laboratory-developed tests (LDTs). Healthcare providers order tests on behalf of patients, and the tests are billed through the hospital or institution. The company processes samples in its CLIA-certified, CAP-accredited, and ISO 15189-accredited laboratory. Revenue is derived from test processing fees charged to healthcare institutions and payers. Tests are offered as send-out tests ordered by licensed healthcare practitioners.

kariusdx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Karius operates a CLIA-certified, CAP-accredited clinical laboratory that delivers laboratory-developed metagenomic sequencing tests on patient plasma and bronchoalveolar lavage (BAL) fluid samples. Its commercial tests — Karius Spectrum and Karius Focus | BAL — detect and identify over 1,000 pathogens (bacteria, fungi, DNA viruses, parasites) and bacterial antimicrobial resistance markers from a single specimen, returning results to the ordering provider typically within one day of sample receipt.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • >50% increased relative diagnostic yield compared to all standard-of-care BAL tests combined in immunocompromised patients with suspected pneumonia
+5 more records
Product overview1 text field

Karius offers a portfolio of metagenomic sequencing diagnostic tests powered by the Karius Helion platform. The core products include Karius Spectrum, a plasma-based test detecting over 1,000 pathogens from a single blood draw, and Karius Focus | BAL, a bronchoalveolar lavage fluid test detecting over 500 pathogens for lung infections. The Helion platform combines Direct-to-Library chemistry, a proprietary clinical-grade database, and AI for real-time genomic analysis, enabling rapid pathogen detection and antimicrobial resistance identification.

Product and service2 records
1Karius Spectrum
CategoryClinical infectious disease diagnostic test
Description

A blood test leveraging plasma metagenomic sequencing of microbial cell-free DNA (mcfDNA) to detect over 1,000 fungi, bacteria, DNA viruses, and parasites associated with deep-seated and difficult-to-diagnose systemic infections, including bacterial antimicrobial resistance markers for 18 pathogens across four resistance classes. Results are typically available within one day of sample receipt and are ordered by licensed healthcare providers on behalf of hospitalized and immunocompromised patients at U.S. hospitals and transplant centers.

2Karius Focus | BAL
CategoryClinical infectious disease diagnostic test
Description

A bronchoalveolar lavage (BAL) fluid-based mcfDNA metagenomic sequencing test designed for detection and classification of over 500 pathogens associated with lung infection. It requires only 1 mL of BAL fluid, returns results within one day of sample receipt, and has demonstrated more than 50% increased relative diagnostic yield compared with all standard-of-care BAL tests combined in a study of 118 immunocompromised patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-23
Description

Karius and Mayo Clinic Laboratories announced a collaboration in April 2026 to make Karius's advanced metagenomic infectious disease diagnostic offerings (Karius Spectrum and Karius Focus | BAL tests) available to order through Mayo Clinic Laboratories. The collaboration includes joint educational initiatives such as co-developed scientific webinars, case-study sessions, and field-based training to raise awareness of the clinical utility of metagenomic diagnostics. Laboratory logistics are streamlined through Mayo Clinic Laboratories' infrastructure, enabling sample submission and test reporting within 24 hours of arrival.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-08
Description

Karius secured a contract with BARDA in August 2024 to expand agnostic detection of pathogens. BARDA is a U.S. government agency responsible for developing and acquiring medical countermeasures against health security threats. This contract supports the development and validation of Karius's next-generation diagnostic capabilities for broad pathogen detection, which aligns with national preparedness priorities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

In April 2023, Karius partnered with eGenesis to develop testing systems for monitoring microbial cell-free DNA in pig organ donors to improve xenotransplantation safety. This partnership supports eGenesis's xenotransplantation programs by providing microbial monitoring for genetically modified pig organs intended for human transplantation. The collaboration addresses a critical need in the emerging field of xenotransplantation where infection monitoring is essential for patient safety.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

T2 Biosystems develops rapid blood-based molecular tests (T2Bacteria, T2Candida) for direct pathogen detection from whole blood, directly competing with Karius Spectrum in the bloodstream infection / immunocompromised patient diagnostic workflow.

TypeDirect peer
Description

Accelerate Diagnostics offers rapid identification and antimicrobial susceptibility testing (AST) directly from positive blood cultures, competing for the same hospital microbiology budgets and bloodstream infection use cases that Karius addresses with mcfDNA sequencing.

TypeBroad incumbent
Description

Global leader in clinical microbiology (culture media, VITEK identification/AST, BioFire FilmArray syndromic panels) that competes broadly with Karius in hospital infectious disease diagnostics, with significantly greater distribution and installed-base reach.

TypeBroad incumbent
Description

Cepheid's GeneXpert system delivers rapid molecular syndromic panels (e.g., Xpert MTB/RIF, blood culture ID) used in the same hospital settings as Karius, providing broad incumbent competition for molecular infectious disease testing budgets.

TypeBroad incumbent
Description

BioFire FilmArray syndromic panels (blood culture identification, pneumonia, meningitis/encephalitis) are widely installed in US hospitals and compete for the same immunocompromised pneumonia and bloodstream infection testing workflows as Karius.

TypeBroad incumbent
Description

BD offers a broad portfolio across microbiology (BD MAX, Phoenix M50, culture media) and molecular diagnostics. Its scale and installed base make it a broad incumbent competitor across hospital infectious disease testing.

TypeEmerging player
Description

Specific Diagnostics is developing rapid phenotypic AST directly from positive blood cultures, partially overlapping with Karius's bloodstream infection use case by targeting faster time-to-susceptibility for hospital stewardship programs.

TypeEmerging player
Description

Selux is developing rapid AST platforms with same-day phenotypic results from positive blood cultures, partially overlapping Karius's bloodstream infection value proposition for hospitals treating immunocompromised patients.

TypeDirect peer
Description

CosmosID provides microbial genomics and metagenomic sequencing services with a curated reference database, closely comparable to Karius's Helion platform in underlying technology and database-driven pathogen identification.

TypeEmerging player
Description

Day Zero Diagnostics is developing blood-based sequencing diagnostics to identify pathogens and predict antibiotic resistance from bloodstream infections, an emerging peer overlapping with Karius Spectrum's core use case.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Karius

Infectious Disease Diagnosticskariusdx.com

Karius is a clinical metagenomics company that delivers rapid infectious disease diagnostics to hospitals and transplant centers, detecting over 1,000 pathogens from a single blood draw via its proprietary Helion sequencing platform, AI-driven reference database, and CLIA-certified laboratory.

What Karius does

Karius, Inc. is a Redwood City, California-based clinical metagenomics company founded in 2014 on intellectual property developed at Stanford University. It operates a CLIA-certified, CAP-accredited, ISO 15189-accredited clinical laboratory that processes microbial cell-free DNA (mcfDNA) sequencing tests on behalf of licensed healthcare providers. Its commercial product portfolio centers on two laboratory-developed tests: Karius Spectrum, a plasma-based test that detects over 1,000 fungi, bacteria, parasites, and DNA viruses from a single blood draw with results typically available within one day, and Karius Focus | BAL, a bronchoalveolar lavage fluid-based test launched in April 2025 that detects over 500 lung-infection pathogens from 1 mL of BAL fluid. Both are powered by the Karius Helion platform, which combines a "Direct-to-Library" chemistry that bypasses DNA extraction, a proprietary curated reference database of 20,000+ microbial sequences, and machine learning models that are continuously refined as additional patient data is processed.

Karius sells these tests as laboratory-developed tests through an enterprise field sales motion to 600+ leading US hospitals and transplant centers, with results delivered through an online portal and specimens transported via covered UPS Next Day Air Early shipping. Revenue is generated per test through institutional and payer billing, with secondary commercial activity in biopharma services (microbial liquid biopsy for clinical trial enrichment, safety monitoring, and patient stratification). The company complements its direct sales channel with Medical Science Liaisons, diagnostic stewardship support, an Investigator-Initiated Studies Grants program, and — announced in April 2026 — a collaboration with Mayo Clinic Laboratories that makes its tests available through Mayo's ordering infrastructure.

The company has raised approximately $354M in cumulative equity and debt funding across multiple rounds, including a $100M round in May 2024 co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, and received FDA Breakthrough Device Designation for its infectious disease test in May 2024. Karius reports that more than 100,000 patient samples have been tested on its platform and that the technology is supported by 300+ peer-reviewed publications. Leadership includes CEO Alec Ford, CSO Tim Blauwkamp PhD, CTO/Business Officer Sivan Bercovici PhD, CMO Bradley Perkins MD, CFO Bill Quirk, CCO Mark Aguillard, and CPO Stacy Aurora, with co-founders Tim Blauwkamp and Mickey Kertesz and Stanford's Steve Quake serving on the scientific advisory board.

Karius firmographics

Firmographics
Name
Karius
Legal name
Karius, Inc.
Website
https://kariusdx.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Karius is a clinical metagenomics company that delivers rapid infectious disease diagnostics to hospitals and transplant centers, detecting over 1,000 pathogens from a single blood draw via its proprietary Helion sequencing platform, AI-driven reference database, and CLIA-certified laboratory.
Ownership category
akta.pro rank

Karius industry classification

Industry
Product category
Infectious Disease Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories

Keywords

  • Metagenomic sequencing diagnostics
  • Infectious disease testing
  • Microbial cell-free DNA
  • Clinical laboratory diagnostics
  • Pathogen detection services

Where Karius is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Karius business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Laboratory Testing Services: Karius operates as a clinical laboratory offering laboratory-developed tests (LDTs). Healthcare providers order tests on behalf of patients, and the tests are billed through the hospital or institution. The company processes samples in its CLIA-certified, CAP-accredited, and ISO 15189-accredited laboratory. Revenue is derived from test processing fees charged to healthcare institutions and payers. Tests are offered as send-out tests ordered by licensed healthcare practitioners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Karius product offering

Product offering

Core offering

Karius operates a CLIA-certified, CAP-accredited clinical laboratory that delivers laboratory-developed metagenomic sequencing tests on patient plasma and bronchoalveolar lavage (BAL) fluid samples. Its commercial tests — Karius Spectrum and Karius Focus | BAL — detect and identify over 1,000 pathogens (bacteria, fungi, DNA viruses, parasites) and bacterial antimicrobial resistance markers from a single specimen, returning results to the ordering provider typically within one day of sample receipt.

Product overview

Karius offers a portfolio of metagenomic sequencing diagnostic tests powered by the Karius Helion platform. The core products include Karius Spectrum, a plasma-based test detecting over 1,000 pathogens from a single blood draw, and Karius Focus | BAL, a bronchoalveolar lavage fluid test detecting over 500 pathogens for lung infections. The Helion platform combines Direct-to-Library chemistry, a proprietary clinical-grade database, and AI for real-time genomic analysis, enabling rapid pathogen detection and antimicrobial resistance identification.

Differentiator

Problem solved

Functional benefit

Products and services

  • Karius Spectrum A blood test leveraging plasma metagenomic sequencing of microbial cell-free DNA (mcfDNA) to detect over 1,000 fungi, bacteria, DNA viruses, and parasites associated with deep-seated and difficult-to-diagnose systemic infections, including bacterial antimicrobial resistance markers for 18 pathogens across four resistance classes. Results are typically available within one day of sample receipt and are ordered by licensed healthcare providers on behalf of hospitalized and immunocompromised patients at U.S. hospitals and transplant centers.
  • Karius Focus | BAL A bronchoalveolar lavage (BAL) fluid-based mcfDNA metagenomic sequencing test designed for detection and classification of over 500 pathogens associated with lung infection. It requires only 1 mL of BAL fluid, returns results within one day of sample receipt, and has demonstrated more than 50% increased relative diagnostic yield compared with all standard-of-care BAL tests combined in a study of 118 immunocompromised patients.

Quantifiable outcome

  • >50% increased relative diagnostic yield compared to all standard-of-care BAL tests combined in immunocompromised patients with suspected pneumonia
  • +5 more outcomes

Companies that use Karius

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Karius technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Karius partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Mayo Clinic LaboratoriescoreChannel Partner/ Reseller/ Distributor · 23 April 2026Karius and Mayo Clinic Laboratories announced a collaboration in April 2026 to make Karius's advanced metagenomic infectious disease diagnostic offerings (Karius Spectrum and Karius Focus | BAL tests) available to order through Mayo Clinic Laboratories. The collaboration includes joint educational initiatives such as co-developed scientific webinars, case-study sessions, and field-based training to raise awareness of the clinical utility of metagenomic diagnostics. Laboratory logistics are streamlined through Mayo Clinic Laboratories' infrastructure, enabling sample submission and test reporting within 24 hours of arrival.
  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 8 August 2024Karius secured a contract with BARDA in August 2024 to expand agnostic detection of pathogens. BARDA is a U.S. government agency responsible for developing and acquiring medical countermeasures against health security threats. This contract supports the development and validation of Karius's next-generation diagnostic capabilities for broad pathogen detection, which aligns with national preparedness priorities.
  • eGenesiscoreStrategic or Co-development Partner · 1 April 2023In April 2023, Karius partnered with eGenesis to develop testing systems for monitoring microbial cell-free DNA in pig organ donors to improve xenotransplantation safety. This partnership supports eGenesis's xenotransplantation programs by providing microbial monitoring for genetically modified pig organs intended for human transplantation. The collaboration addresses a critical need in the emerging field of xenotransplantation where infection monitoring is essential for patient safety.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Karius competitors and assessment

Company assessment

Direct peers

  • T2 Biosystems: T2 Biosystems develops rapid blood-based molecular tests (T2Bacteria, T2Candida) for direct pathogen detection from whole blood, directly competing with Karius Spectrum in the bloodstream infection / immunocompromised patient diagnostic workflow.
  • Accelerate Diagnostics: Accelerate Diagnostics offers rapid identification and antimicrobial susceptibility testing (AST) directly from positive blood cultures, competing for the same hospital microbiology budgets and bloodstream infection use cases that Karius addresses with mcfDNA sequencing.
  • CosmosID: CosmosID provides microbial genomics and metagenomic sequencing services with a curated reference database, closely comparable to Karius's Helion platform in underlying technology and database-driven pathogen identification.

Broad incumbents

  • bioMérieux: Global leader in clinical microbiology (culture media, VITEK identification/AST, BioFire FilmArray syndromic panels) that competes broadly with Karius in hospital infectious disease diagnostics, with significantly greater distribution and installed-base reach.
  • Cepheid (Danaher): Cepheid's GeneXpert system delivers rapid molecular syndromic panels (e.g., Xpert MTB/RIF, blood culture ID) used in the same hospital settings as Karius, providing broad incumbent competition for molecular infectious disease testing budgets.
  • BioFire Diagnostics: BioFire FilmArray syndromic panels (blood culture identification, pneumonia, meningitis/encephalitis) are widely installed in US hospitals and compete for the same immunocompromised pneumonia and bloodstream infection testing workflows as Karius.
  • Becton Dickinson (BD): BD offers a broad portfolio across microbiology (BD MAX, Phoenix M50, culture media) and molecular diagnostics. Its scale and installed base make it a broad incumbent competitor across hospital infectious disease testing.

Emerging players

  • Specific Diagnostics: Specific Diagnostics is developing rapid phenotypic AST directly from positive blood cultures, partially overlapping with Karius's bloodstream infection use case by targeting faster time-to-susceptibility for hospital stewardship programs.
  • Selux Diagnostics: Selux is developing rapid AST platforms with same-day phenotypic results from positive blood cultures, partially overlapping Karius's bloodstream infection value proposition for hospitals treating immunocompromised patients.
  • Day Zero Diagnostics: Day Zero Diagnostics is developing blood-based sequencing diagnostics to identify pathogens and predict antibiotic resistance from bloodstream infections, an emerging peer overlapping with Karius Spectrum's core use case.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Karius social profiles

Digital presence

Karius compliance and trust

Trust signal

Compliance9 records

Karius financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Karius leadership team

Management profile

Number of profiles

Profiles12 records

Karius funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Karius M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karius

What does Karius do?

Karius operates a CLIA-certified, CAP-accredited clinical laboratory that delivers laboratory-developed metagenomic sequencing tests on patient plasma and bronchoalveolar lavage (BAL) fluid samples. Its commercial tests — Karius Spectrum and Karius Focus | BAL — detect and identify over 1,000 pathogens (bacteria, fungi, DNA viruses, parasites) and bacterial antimicrobial resistance markers from a single specimen, returning results to the ordering provider typically within one day of sample receipt.

Is Karius a public or private company?

Karius is a private company. It is classified as venture growth investor backed and is currently operating.

When was Karius founded?

Karius was founded in 2014. It employs 101 to 250 people.

Where is Karius based?

Karius is headquartered in Redwood City, United States, in the North America region.

How does Karius make money?

One revenue line is on record: clinical Laboratory Testing Services.

Who are Karius's main competitors?

Direct peers on record are T2 Biosystems, Accelerate Diagnostics and CosmosID. Broad incumbents are bioMérieux, Cepheid (Danaher), BioFire Diagnostics and Becton Dickinson (BD). Emerging players are Specific Diagnostics, Selux Diagnostics and Day Zero Diagnostics.

Does Karius have an API?

No public API is recorded for Karius.

What industry is Karius in?

Karius's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAFAMAD, Microbiology & Infectious Disease Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogKarius, Inc. Announces Collaboration to Extend Access to Infectious Disease DiagnosticsKarius, Inc. and Mayo Clinic Laboratories announced a collaboration to make Karius Spectrum and Focus tests available through Mayo Clinic Laboratories. The tests use metagenomic sequencing to detect pathogens from plasma and bronchoalveolar lavage fluid with 24-hour processing. The partnership includes joint educational initiatives and streamlined sample submission.openPR.comEmerging Growth Patterns Driving Expansion in the Xenotransplantation MarketThe xenotransplantation market is projected to reach $23.51 billion by 2030, growing at a CAGR of 8.2%, driven by increased clinical trials, gene-editing investments, and stronger industry partnerships. In October 2023, United Therapeutics Corporation acquired Miromatrix Medical for $91 million to expand its organ production technologies, including xenotransplantation and regenerative medicine. In April 2023, Karius partnered with eGenesis to develop testing systems for monitoring microbial cell-free DNA in pig organ donors to improve xenotransplantation safety.LinkedInSoftBank Investment AdvisersAlec Ford, CEO of Karius, discusses the application of AI-powered genomic testing to improve infectious disease diagnosis by analyzing microbial DNA against a database of over 1,000 pathogens. The technology processes millions of data points to identify the specific cause of infections, aiming to provide clinicians with precise data for life-saving decisions and less invasive patient care.F6s33 Top Molecular Diagnostics Companies · November 2025The article presents a curated list of 33 top molecular diagnostics companies and startups as of November 2025, highlighting innovations in portable devices, genomic testing, and infectious disease detection. Featured entities include BIOPIX-T, VetDiag Genomix, Listen Therapeutics, FrontierSeq, Nanoplasmas, Aubaree Group, Scope Fluidics, MOL Diagnostics, and Karius. These organizations are noted for their development of advanced diagnostic tools ranging from point-of-care sensors to next-generation sequencing platforms.FunguseducationhubA Virtual Town Hall EventPartners for Advancing Clinical Education and Terranova Medica, LLC jointly provided an accredited virtual town hall event focused on advanced molecular techniques for diagnosing invasive fungal infections. The session featured experts Dr. Luis Ostrosky-Zeichner and Angel Desai discussing the clinical application of PCR and mNGS testing in various patient populations. The activity was supported by an independent educational grant from Karius.InsideprecisionmedicinePulmonary Precision: Karius Launches Metagenomic Test for Lung InfectionsKarius launched the Karius Focus | BAL test, a metagenomic cfDNA diagnostic for lung infections in immunocompromised patients. The test analyzes BAL fluid to detect over 500 pathogens, addressing a 25% mortality rate for suspected pneumonia in this group. It complements Karius's plasma test, which covers over 1,000 pathogens.Clinical Lab ProductsKarius Launches Karius Focus | BALKarius, Inc. has launched Karius Focus | BAL, a rapid microbial cell-free DNA test designed to improve pathogen detection in lung infections for immunocompromised patients. The test can identify over 500 pathogens from just 1 mL of bronchoalveolar lavage (BAL) fluid with results available within one day, and became available nationwide on April 28, 2025. The new product complements the existing Karius Spectrum plasma test and aims to address diagnostic gaps where standard-of-care testing frequently fails to identify causative pathogens.InvestmentreportsAlec Ford, KariusKarius secured $100 million in a Series C funding round led by Khosla Ventures to support commercial expansion and the development of its metagenomic diagnostic test. The company has over 400 US hospitals as clients and is leveraging FDA Breakthrough Device Designation to accelerate regulatory approval for diagnosing pneumonia in immunocompromised patients.BBCAI is trained to spot warning signs in blood testsAI is being used to develop blood tests that detect early signs of ovarian cancer and pneumonia. A team at Memorial Sloan Kettering trained a machine-learning algorithm on nanotube data from about 100 patients, achieving better accuracy than current biomarkers. Karius uses AI to identify pneumonia pathogens in 24 hours, reducing testing costs.